Actavis hit with IP suit over prostate cancer drug


Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi (enzalutamide), a treatment for prostate cancer.

Actavis, Astellas, Medivation, Prostate Therapeutics, The Regents of the University of California, Xtandi, ANDA